First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC
By Kara Nyberg, PhD Adding sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. In the randomized, placebo-controlled, phase III […] Read more
Deeper Dive: A Plethora of Prediction Models
Annette McWilliamsBy Annette McWilliams, MBBS, FRACP, MD, FRCPSC In reference to: Nemesure B, Clouston S, Albano D, Kuperberg S, Bilfinger TV. Will that pulmonary nodule become cancerous? A risk prediction model […] Read more
Re-establishing protocols and systems for accurate and timely diagnosis and staging despite fears and high volume is critical to patient survival. Read more
Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?
Karen L. ReckampBy Karen L. Reckamp, MD When advanced NSCLC is diagnosed, the word “cure” is avoided; we focus on palliation of symptoms with prolonged survival. Unfortunately, there are more than 200,000 […] Read more
Small Steps Forward in SCLC: Is a Giant Leap on the Horizon?
Carl M. GayThe absence of an OS benefit in more than 3 decades of clinical trials for extensive-stage SCLC (ES-SCLC) had become an all-too-familiar refrain among the introductions to numerous publications and […] Read more
Immune Checkpoint Inhibitors Have Led to Substantial Improvements in Lung Cancer but Are Still Not a ‘Cure’
Edward B. GaronBy Edward B. Garon, MD Immune checkpoint inhibitors have dramatically changed the treatment of patients with lung cancer. The degree of efficacy seen with these agents would have been nearly […] Read more
Liquid biopsy for early lung cancer detection and cancer interception
Christian Rolfo, MD, PhD, MBA, DrhcBy Christian Rolfo, MD, PhD, MBA, Dr.hc. Over the past several years, three large randomized clinical trials demonstrated that low-dose computed tomography (LDCT) screening is a valuable method for lung […] Read more
The Chen-Huang Center for EGFR-Mutant Lung Cancers Represents a ‘Concentrated and Focused Effort’ in Studying Th is Disease Subset
Posted: August 21, 2020 The Chen-Huang Center for EGFR Mutant Lung Cancers, founded at Dana-Farber Cancer Institute earlier this year, is poised to make advances in the study and treatment […] Read more
By Ben Solomon, MBBS, PhD, FRACP Posted: August 21, 2020 ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur in never smokers and […] Read more
By Joy Curzio Posted: August 21, 2020 The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), has a 2019 […] Read more